Spluttering US Generics Landscape Shows Signs Of Promise In Q2
Teva, Sandoz, Viatris Make Positive Noises In Q2 Readout
High-value launches and an improving broader landscape for generic pricing provided a fillip for some US generics manufacturers in the second quarter, although others disclosed that they were still weathering the storm as the end of the year approaches.
You may also be interested in...
Teva has wrapped up an earlier deal with Sanofi that will see the French giant take command of its novel TL1A inhibitor currently in a Phase IIb study for ulcerative colitis and Crohn’s disease.
Generics Bulletin previews the most noteworthy and anticipated events for December 2023.
“A lot of companies are hurting because of the higher interest rates,” one major CEO observed recently, summing up a year which saw little headline-grabbing news on the M&A front for generic and biosimilar sponsors.